Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

January 12, 2018: By Joan McKenna

Ohr Pharmaceutical announced Jan. 5 that squalamine used in combination with Lucentis failed to meet its primary efficacy endpoint in a Phase III study in patients with wet age-related macular degeneration (AMD).

The endpoint was mean visual acuity gain at nine months. Subjects receiving topically administered squalamine with monthly Lucentis injections (n=119) achieved a mean gain of 8.33 letters from baseline, while those treated with Lucentis monotherapy (n=118) achieved 10.58 letters. There were no differences in the safety profile between the two treatment groups.

Jason Slakter, MD, chief executive officer of Ohr, expressed disappointment and said, “We are grateful to the patients and physicians who participated in the clinical trial. Based on these results, we intend to evaluate strategic alternatives to maximize shareholder value.”

In February 2017, Ohr paused enrollment in the Phase III trial at 200 following the failure of other retinal combo therapies. Ohr said the move would enable it to potentially confirm the visual acuity benefits observed in the patient population it identified as the most likely to benefit from squalamine combination therapy.

Squalamine is intended to inhibit vascular endothelial growth factor, platelet-derived growth factor, and basic fibroblast growth factor. It is based on a compound found in the tissues of the dogfish shark. The FDA granted it fast track designation for wet AMD.

Ohr acquired squalamine from by Genaera Pharma in 2009 as Genaera liquidated its assets.

In April 2017, Ohr closed a $14.2 million public offering.

In December 2016, the company closed a $7.8 million public offering.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023